Skip to main content

CSL Coronavirus Information

We are committed to continuing to provide our medicines to patients around the world, while pursuing COVID-19 treatments through a variety of collaborations.

Paul Perreault

COVID-19: A Message from Our CEO

"As the COVID-19 pandemic evolves, CSL remains committed to safeguarding our patients, our donors and our people. In keeping with our values-based culture, CSL has taken precautions to ensure our employees and our facilities remain safe so we can continue to deliver on our promise to patients and public health." - Paul Perreault, CEO & Managing Director, CSL Limited

Watch Online: Collaborating on a COVID-19 Treatment

We’re working with other leading plasma medicine companies on a “hyperimmune.” Learn more about an ongoing clinical trial and our efforts.

Watch video

News Releases & Updates

CSL’s Global Role in Battling COVID-19

10 DECEMBER 2020: Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19.

 

COVID-19 Update

9 DECEMBER 2020: CSL continues to provide medicines to patients around the world.

 

First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine

8 OCTOBER 2020: The anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19.

The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate

5 JUNE 2020: CEPI, the Coalition for Epidemic Preparedness Innovations, CSL (ASX:CSL) and The University of Queensland (UQ) today announced that they have entered into a new, significant partnering agreement to accelerate the development, manufacture and distribution of a COVID-19 vaccine candidate which has been pioneered by researchers at UQ.

 

CSL Behring and SAB Biotherapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic

8 APRIL 2020: COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology, on-track for clinical evaluation as early as summer.

 

Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy

6 APRIL 2020: Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19.